Apatinib is the highest selectivity inhibitor of VEGFR-2 targeting the intracellular ATP-binding site of the receptor.[6,14] In a randomized, open-label, multicenter phase II clinical study, the effects of 2 different doses of apatinib for patients with advanced HCC as the first-line therapy on the time to progression (TTP) and median OS were compared. Here, KDR is linked to hepatocellular carcinoma.